In order to strengthen its cardiovascular portfolio, Bristol Myers Squibb (BMS) has entered into a development and commercialisation agreement with Avidity Biosciences to create RNA-based medicines for cardiovascular diseases. Through the deal, which is worth up to US$2.275 B, the companies will leverage Avidity’s antibody oligonucleotide conjugate (AOCs) platform technology, which combines the specificity of monoclonal antibodies with the precision of oligonucleotide therapies. The partnership aligns with BMS’ R&D strategy, as the company has invested heavily in the cardiovascular space in recent years.